<DOC>
	<DOC>NCT02205476</DOC>
	<brief_summary>Study is a multicenter, two-part, open-label phase II study in adults, evaluating the safety and long-term efficacy of PF-06473871 one year after surgical revision and treatment with PF-06473871.</brief_summary>
	<brief_title>A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cicatrix, Hypertrophic</mesh_term>
	<criteria>Subjects previously randomized to Pfizer clinical study B5301001. Subjects must be able to tolerate up to a 3 hour scar revision surgery under sedation and local anesthesia. Pregnant female subject; breastfeeding female subjects; male subjects with partners currently pregnant. Any previous history of intolerable adverse reactions to PF06473871, such as serious adverse events attributed to study drug or having been withdrawn due to AE in prerequisite study B5301001.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>57 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>open-label</keyword>
	<keyword>safety</keyword>
	<keyword>hypertrophic scar revision surgery</keyword>
</DOC>